Borrelia Infections is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Borrelia Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Borrelia Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Borrelia Infections overview
Borrelia infections are bacterial diseases caused by different species of Borrelia, such as Borrelia burgdorferi, Borrelia afzelii, and Borrelia garinii. These bacteria are transmitted to humans by the bite of infected ticks or lice. Borrelia infections can cause various clinical manifestations, depending on the species and the stage of infection. The most common forms of Borrelia infections are Lyme disease and relapsing fever. Lyme disease is characterized by a circular rash at the site of the tick bite, followed by symptoms such as fever, fatigue, headache, arthritis, neurological problems, and heart problems. Relapsing fever is characterized by recurrent episodes of fever, chills, headache, muscle pain, and rash. Borrelia infections are diagnosed by medical history, physical examination, and laboratory tests that detect antibodies to the bacteria. Borrelia infections are treated with antibiotics, such as doxycycline, amoxicillin, ceftriaxone, or penicillin. Prevention of Borrelia infections involves avoiding tick bites and removing ticks promptly.
For a complete picture of PTSR and LoA scores for drugs in Borrelia Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
